Medical devices behemoth Stryker agreed to buy Inari Medical for $4.9 billion. Inari stock catapulted Tuesday on the news.

Charles R. Goulding and Preeti Sulibhavi examine how Stryker's acquisition of Inari Medical is set to transform vascular care ...

Inari Medical (NARI – Research Report) received a Hold rating and price target from William Blair analyst Margaret Kaczor today. The ...

Inari Medical Inc is a medical device company ... The FlowTriever System product is used for the treatment of pulmonary embolism, InThrill system to treat small vessel thrombosis, LimFlow system ...

Inari Medical (NARI – Research Report) received a Hold rating and price target from BTIG analyst Marie Thibault today. The company’s shares ...

Inari shareholders are getting a fair price ... and has not really been a player in venous markets like pulmonary embolism (or PE), deep vein thrombosis (or DVT), limb ischemia, and the like ...

Inari is poised to enhance Stryker's footprint ... These solutions are designed to treat peripheral vascular conditions such as pulmonary embolism and deep vein thrombosis. They claim to remove ...

Inari Medical Background Information (This ... deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of deep ...

NEW YORK, Jan 6 (Reuters) - Medical-device maker Stryker (SYK.N), opens new tab on Monday agreed to acquire Inari Medical (NARI.O), opens new tab, which makes devices that treat patients with ...

Inari Medical (NASDAQ:NARI – Free Report) had its price target increased by Piper Sandler from $52.00 to $80.00 in a report issued on Tuesday morning,Benzinga reports. The brokerage currently has a ...